Table 1.

Dose-escalation and dose limiting toxicities (DLT).

Dose Level	Veliparib (mg AM/PM)	Enrolled mut/wt	Evaluable mut/wt	DLT mt/wt	Grade – DLT**
1	50/50	7/3	7/3	1*/0	Grade 2 thrombocytopenia, later deemed related to disease progression, necessitated hold of veliparib > 2 weeks
2	100/50	3/3	3/3
3	100/100	3/3	3/3
4	150/100	3/3	3/3
5	150/150	3/3	3/3
6	200/200	4/3	3/3
7	300/300	6/3	4/3
8	400/400	34/7	27/6	1/1	G3 nausea / G2 seizure
9	500/500	7/0	6/0	1/0	G2 seizure

^*DLT experienced before start of parallel enrollment of BRCAmt and BRCAwt cohorts.

^**Per protocol, any seizure occurring in a patient on this study was considered a DLT, unless in the setting of CNS metastases.